

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment


Qian Cai,^{†,‡,||} Haiying Sun,^{†,||} Yuefeng Peng,^{†,‡,||} Jianfeng Lu,[†] Zanita Nikolovska-Coleska,[†] Donna McEachern,[†] Liu Liu,[†] Su Qiu,[†] Chao-Yie Yang,[†] Rebecca Miller,[†] Han Yi,[†] Tao Zhang,[‡] Duxin Sun,[‡] Sanmao Kang,[§] Ming Guo,[§] Lance Leopold,[§] Dajun Yang,[§] and Shaomeng Wang^{*,†}

[†]Comprehensive Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States

[‡]Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States

[§]Ascenta Therapeutics, 101 Lindenwood Drive, Malvern, Pennsylvania 19355, United States

ABSTRACT: We report the discovery and characterization of SM-406 (compound 2), a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). This compound binds to XIAP, cIAP1, and cIAP2 proteins with K_i of 66.4, 1.9, and 5.1 nM, respectively. Compound 2 effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines. It has good oral bioavailability in mice, rats, non-human primates, and dogs, is highly effective in induction of apoptosis in xenograft tumors, and is capable of complete inhibition of tumor growth. Compound 2 is currently in phase I clinical trials for the treatment of human cancer.



INTRODUCTION

Apoptosis is a cellular process critical to the normal development and homeostasis of multicellular organisms. Dysfunction of the apoptosis machinery has been linked to many human diseases, including cancer, inflammation, and neurological conditions.^{1–3}

Defects in the apoptosis machinery confer on cancer cells resistance to therapeutic agents and are known to compromise current anticancer therapies, leading ultimately to their failure.^{2–4} Avoidance of apoptosis is a hallmark of human cancer,⁴ and targeting key apoptosis regulators with the goal of overcoming the evasion of apoptosis by tumor cells is an exciting therapeutic strategy for the treatment of human cancer.¹

The inhibitors of apoptosis proteins (IAPs) are a class of key apoptosis regulators.^{5–7} Extensive studies have shown that although their role is not limited to regulation of apoptosis,^{9,10} X-linked IAP (XIAP) and cellular IAP 1 and IAP 2 (cIAP1 and cIAP2) are in central positions as inhibitors of death signals that proceed through a number of pathways.^{5–7} XIAP functions as a potent apoptosis inhibitor by directly binding to and effectively inhibiting three caspases, caspase-3 and -7, and -9.^{5–8} The third BIR domain (BIR3) of XIAP selectively targets caspase-9,^{15,16} while the BIR2 domain, together with the linker preceding it, inhibits both caspase-3 and caspase-7.^{17–19} By inhibiting these three caspases, XIAP plays a central role in the inhibition of apoptosis in both death receptor-mediated and mitochondria-mediated pathways.^{5–7} cIAP1 and cIAP2 were originally identified through their ability to interact directly with tumor necrosis factor associated factor 2 (TRAF2).²⁰ Through their interactions with TRAF2, cIAP1 and cIAP2 are recruited to TNF-receptor-1- and TNF-receptor-2-associated complexes where they suppress caspase-8 activation and death-receptor-mediated apoptosis.⁵ Furthermore, IAPs

also influence a multitude of other cellular processes, such as ubiquitin (Ub) dependent signaling events that regulate activation of nuclear factor κ B (NF κ B), which in turn drive the expression of genes important for inflammation, immunity, cell migration, and cell survival.¹⁰ IAPs also modulate signaling events that promote the activation of cell motility kinases and metastasis,¹¹ and they regulate mitogenic kinase signaling, proliferation, and mitosis. Many of these cellular processes are frequently deregulated in cancer and contribute directly or indirectly to disease initiation, tumor maintenance, and/or progression.^{12,13} IAP proteins are therefore attractive new cancer therapeutic targets.^{12–14}

Smac/DIABLO (second mitochondria-derived activator of caspases or direct IAP binding protein with low pI) has been identified as an endogenous antagonist of XIAP, cIAP1, and cIAP2.^{21,22} It nullifies the inhibition by XIAP of caspase-9 by binding to the BIR3 domain in XIAP through its Ala-Val-Pro-Ile (AVPI) tetrapeptide binding motif (1 in Figure 1) and directly competing with a similar tetrapeptide, Ala-Thr-Pro-Phe (ATPF) motif, in caspase-9.^{15,16,23,24} It has been proposed that Smac protein binds to XIAP BIR2 via its AVPI motif, preventing the binding of XIAP to caspase-3/caspase-7.²⁵ cIAP1 interacts with Smac through its BIR3 domain but not other BIR domains.²⁶ Interestingly, in HeLa cells, expression of Smac protein selectively induces degradation of cIAP1/2 but not XIAP.²⁷

The interaction of Smac with these IAP proteins involves the AVPI tetrapeptide motif in Smac and a well-defined groove in the IAP proteins, and there is considerable interest in the design of

Received: November 22, 2010

Published: March 28, 2011




Figure 1. Chemical structures of Smac AVPI peptide, a potent and orally active Smac mimetic **2**, its inactive control **3**, a biotinylated analogue **4**, and a fluorescently tagged analogue **5**.

nonpeptidic small molecules as a new class of anticancer drugs that mimic the Smac AVPI peptide and antagonize these IAP proteins.^{28,29} Employing a structure-based design strategy based upon the crystal structure of Smac in a complex with XIAP BIR3 protein, we have designed and synthesized several classes of conformationally constrained non-peptide Smac mimetics.^{30–38} Our efforts have led to the discovery of SM-406 (**2** in Figure 1) as a potent and orally bioavailable Smac mimetic that possesses all the desirable properties as a drug candidate for clinical development, which has subsequently been advanced into phase I clinical trials. In this paper, we describe the design, synthesis, and *in vitro* and *in vivo* evaluations of compound **2** as a potent and orally active Smac mimetic.

CHEMISTRY


The syntheses of **2**, an inactive analogue **3** (SM-428), a biotinylated analogue **4** (BL-SM-406), and a fluorescently tagged compound **5** (FL-SM-406) are outlined in Scheme 1, and their chemical structures are shown in Figure 1.

For the synthesis of all these compounds, the common key intermediate compound **6** was prepared using our previously reported method.³⁵ Condensation of **6** with isovaleryl chloride followed by hydrolysis of the methyl ester gave the free acid **7** and condensation of which with diphenylmethylamine yielded the amide **8**. Removal of the Boc protecting group from **8** gave an ammonium salt, which upon condensation with *L*-*N*-Boc-*N*-methylalanine followed by removal of the Boc protecting group gave compound **2**.

Alternatively, condensation of the ammonium salt with *L*-*N*α-Boc-*N*α-methyltryptophan and subsequent removal of the Boc protecting group yielded the designed inactive analogue **3**.

For the synthesis of biotinylated analogue **4**, condensation of compound **9** with *N*-carbobenzoxy- ϵ -aminocaproic acid (*Z*-6-aminohexanoic acid) furnished an amide, mesylation of which, followed by substitution of the mesylate with sodium azide, provided the azide **10**. Condensation of **7** with *S*-1-phenylprop-2-yn-1-amine yielded an amide. Removal of the Boc protecting group from this amide followed by condensation of the resulting ammonium salt with *L*-*N*-Boc-*N*-methylalanine afforded amide **11**. Cycloaddition of **11** with **10** under the influence of CuSO₄ and sodium *L*-ascorbate furnished a triazole. Removal of the Cbz protecting group in this triazole followed by condensation of the resulting amine with (+)-biotin *N*-hydroxysuccinimide ester yielded a biotinylated amide, from which removal of the Boc protecting group gave the biotinylated analogue compound **4**.

For the synthesis of fluorescently tagged analogue **5**, condensation of compound **9** with benzyl chloroformate furnished a carbamate, for which mesylation of the hydroxyl group and substitution of the mesylate with sodium azide provided an azide **12**. Cycloaddition of **11** with **12** in the presence of CuSO₄ and sodium *L*-ascorbate furnished a triazole. Removal of the Cbz protecting group in this triazole followed by condensation of the resulting amine with 5-carboxyfluorescein *N*-succinimidyl ester yielded an amide. Removal of the Boc protecting group from this amide gave the fluorescently tagged analogue compound **5**.

Scheme 1. Synthesis of compounds 2–5^a

^a Reagents and conditions: (a) i. isovaleryl chloride, *N,N*-diisopropylethylamine, CH_2Cl_2 ; ii. Two N LiOH, 1,4-dioxane, 82% over two steps; (b) aminodiphenylmethane, EDC, HOBT, *N,N*-diisopropylethylamine, CH_2Cl_2 , 83%; (c) i. Four N HCl in 1,4-dioxane, methanol; ii. *L*-*N*-Boc-*N*-methylalanine, EDC, HOBT, *N,N*-diisopropylethylamine, CH_2Cl_2 ; iii. Four N HCl in 1,4-dioxane, methanol, 74% over three steps; (d) i. Four N HCl in 1,4-dioxane, methanol; ii. *L*-Boc-*N*-methyl-tryptophan, EDC, HOBT, *N,N*-diisopropylethylamine, CH_2Cl_2 ; iii. Four N HCl in 1,4-dioxane, methanol, 63% over three steps; (e) i. *Z*-6-aminohexanoic acid, EDC, HOBT, *N,N*-diisopropylethylamine, CH_2Cl_2 ; ii. MsCl, Et_3N , CH_2Cl_2 ; iii. NaN_3 , DMF, 110 °C, 49% over three steps; (f) i. *S*-1-phenylprop-2-yn-1-amine, EDC, HOBT, *N,N*-diisopropylethylamine, CH_2Cl_2 ; ii. Four N HCl in 1,4-dioxane, methanol; iii. *L*-*N*-Boc-*N*-methyl-alanine, EDC, HOBT, *N,N*-diisopropylethylamine, 69% over three steps; (g) i. 10, CuSO_4 , sodium *L*-ascorbate, *t*-BuOH- H_2O 1:1; ii. H_2 , 10% Pd-C, methanol; iii. (+)-biotin *N*-hydroxysuccinimide ester, *N,N*-diisopropylethylamine, CH_2Cl_2 ; iv. Four N HCl in 1,4-dioxane, MeOH, 43% over four steps; (h) i. CbzCl, Et_3N , CH_2Cl_2 ; ii. MsCl, Et_3N , CH_2Cl_2 ; iii. NaN_3 , DMF, 66% over three steps; i. 11, CuSO_4 , sodium *L*-ascorbate, *t*-BuOH- H_2O 1:1; ii. H_2 , 10% Pd-C, methanol; iii. 5-Carboxyfluorescein *N*-succinimidyl ester, *N,N*-diisopropylethylamine, CH_2Cl_2 ; iv. Four N HCl in 1,4-dioxane, MeOH, 34% over four steps.

RESULTS AND DISCUSSION

Compound 2 was designed to mimic the interaction of the Smac AVPI peptide with XIAP BIR3 protein. The binding of the Smac AVPI peptide complexed with XIAP BIR3 in the crystal structure²³ of Smac protein and the predicted binding model of 2 in complex with XIAP BIR3 are shown in Figure 2. Compound 2 appears to mimic closely the AVPI peptide in both hydrogen bonding and hydrophobic interactions with XIAP but has additional hydrophobic contacts with W323 of XIAP. On the basis of this model, the terminal methylamino group in 2 inserts into a small, hydrophobic binding pocket associated with W310 in XIAP BIR3. Hence, replacement of the methyl group in 2 with a bulky 3-methyl-1*H*-indole group disrupts the optimal interaction of 2 with XIAP BIR3, which results in an inactive compound 3.

To probe the cellular targets for our designed Smac mimetics, we have designed the biotinylated analogue 4. Modeling suggests that the pro-(*S*)-phenyl group in compound 2, without contact with the XIAP protein, is exposed. Accordingly, this phenyl group was replaced by a triazole group. The biotinylated analogue 4 was synthesized using a highly efficient “click chemistry” method.³⁹ To accurately determine the binding affinities of our Smac mimetics, we have designed and synthesized a fluorescently




Figure 2. Structure-based design of conformationally constrained Smac mimetics. (a) Crystal structure of Smac in complex with XIAP BIR3. For clarity, only the AVPI peptide in Smac is shown. (b) Superposition of the predicted binding model of compound 2 in complex with BIR3 on the crystal structure of Smac AVPI peptide complexed with XIAP BIR3. The carbon atoms of AVPI peptide and compound 2 are shown in yellow and green, respectively, and the nitrogen and oxygen atoms in both ligands are shown in blue and red, respectively. The protein is represented as its solvent accessible surface and colored by atom types (carbon, gray; nitrogen, blue; oxygen, red). Hydrogen bonds are shown in dashed light blue lines.

tagged compound 5 for further optimization of fluorescence polarization (FP) assays.




Figure 3. Saturation curves of fluorescently tagged compound 5 to (A) XIAP BIR3 protein, (B) cIAP1 BIR3 protein, and (C) cIAP2 BIR3 protein. The standard deviation for the K_d value to each protein was calculated from three independent experiments.




Figure 4. Determination of the binding affinities of compounds 2, 3, and the Smac AVPI peptide to (A) XIAP BIR3, (B) cIAP1 BIR3, and (C) cIAP2 BIR3 using sensitive and quantitative fluorescence polarization assays. The standard deviation for the IC_{50} value to each protein was calculated from three independent experiments.

Saturation experiments showed that the fluorescently tagged compound 5 has K_d of 4.4 nM to XIAP BIR3 protein, 0.7 nM to cIAP1 BIR3 protein, and 1.9 nM to cIAP2 BIR3 protein (Figure 3). Furthermore, the dynamic range (Δ mP) for each protein is more than 100, providing a robust signal for the development of competitive FP assays for accurate and quantitative determination of the binding affinities of designed Smac mimetics.

By use of compound 5 as a tracer, a set of competitive FP assays were developed and optimized for XIAP BIR3, cIAP1 BIR3, and cIAP2 BIR proteins. The binding affinities of compounds 2 and 3 and the Smac AVPI peptide to these IAP proteins were determined using these assays (Figure 4). Compound 2 binds to XIAP BIR3, cIAP1 BIR3, and cIAP2 BIR3 proteins with K_i of 66.4, 1.9, and 5.1 nM, respectively. The designed inactive control 3 has minimal binding to these IAP proteins at 10 μ M. Under the same assay conditions, the Smac AVPI peptide binds to XIAP BIR3, cIAP1 BIR3, and cIAP2 BIR3 proteins with K_i of 3.6 μ M, 184 nM, and 316 nM, respectively. Hence, compound 2 binds to these three IAP proteins with 50–100 times higher affinities than the Smac AVPI peptide.

Since XIAP BIR3 binds to and inhibits caspase-9,¹⁶ we determined if 2 can effectively antagonize XIAP BIR3 and so promote the activity of caspase-9 (Figure 5). In a cell-free functional assay, addition of cytochrome *c* and dATP into the MDA-MB-231 cell lysates robustly activates caspase-9, as measured with Z-LEHD-AFC, a substrate specific to caspase-9. Addition of 500 nM XIAP BIR3 effectively suppresses caspase-9 activity, and compound 2 dose-dependently restores it. At 1 μ M, twice that of the XIAP BIR3




Figure 5. Functional antagonism of compound 2 against XIAP BIR3 to restore caspase-9 activity in a cell-free assay. Compound 3 was used as the control compound.

concentration, 2 completely antagonizes XIAP and restores the activity of caspase-9, consistent with its high binding affinity to XIAP BIR3. The inactive control, 3, at concentrations as high as 100 μ M fails to antagonize XIAP and to promote caspase-9 activity. Compound 2 is therefore a potent antagonist of XIAP BIR3 protein in this cell-free system.

Several recent studies have demonstrated that Smac mimetics induce rapid degradation of cIAP1 and that such degradation is a key early event in apoptosis induction by Smac mimetics as single agents in cancer cells.^{40–44} Since 2 binds to cIAP1 with K_i = 1.9 nM, we evaluated its ability to induce cIAP1 degradation in the MDA-MB-231




Figure 6. Compound 2 induces rapid cIAP-1 degradation in the MDA-MB-231 cancer cell line. Cells were treated with compound 2 as indicated, and Western blot analysis was performed using specific antibody against cIAP1 and actin.




Figure 7. Biotin–streptavidin pull-down experiments to probe the binding of compounds 2 and 3 to cellular XIAP and cIAP1 in the MDA-MB-231 breast cancer cell lysates using biotinylated compound 4.




Figure 8. Inhibition of cell growth by compounds 2 and 3 in the MDA-MB-231 breast cancer and SK-OV-3 ovarian cancer cell lines, as determined in a water-soluble tetrazolium (WST) cell proliferation assay. Four independent experiments were performed for each compound in each cell line.

cancer cells and the associated kinetics, with the results shown in Figure 6. Compound 2 effectively induces cIAP1 degradation at concentrations as low as 10 nM, consistent with its very high binding affinity to cIAP1. Induction of cIAP1 degradation by 2 is also very rapid; treatment of MDA-MB-231 cells by 2 at 100 nM for 15 min causes complete degradation of the cIAP1 protein. Thus, compound 2 is highly potent and effective in induction of rapid cIAP1 degradation.

To probe the cellular targets for 2, we have designed and synthesized compound 4, a biotinylated analogue of 2. Compound 4 binds to recombinant XIAP, cIAP1, and cIAP2/BIR3 proteins with K_i of 25.9, <1, and 1.7 nM, respectively. We have performed streptavidin–biotin pull-down experiments with 4 and competitive assays to probe the cellular targets of 2 in the MDA-MB-231 cell lysates, and the results are given in Figure 7. In the MDA-MB-231 cells that have high levels of XIAP and cIAP1 proteins but very low levels of cIAP2 protein, biotinylated compound 4 dose-dependently pulls down the cellular XIAP and cIAP1 proteins. In the competitive experiment, 2 blocks the

interaction of cellular XIAP/cIAP1 with compound 4 in a dose-dependent manner while the inactive control 3 fails to do so. These pull-down experiments show that, consistent with the FP-based binding data using recombinant IAP proteins, both 2 and 4 bind to cellular XIAP and cIAP1 proteins.

Screening of 2 against more than 100 human cancer cell lines revealed that it is effective in inhibition of cell growth in approximately 15% of these cell lines and its activity is not limited to a single tumor type. For example, in a 4-day WST assay, 2 potently inhibits cell growth in the MDA-MB-231 breast and SK-OV-3 ovarian cancer cell lines with IC_{50} of 144 and 142 nM, respectively (Figure 8). The inactive control 3 has $IC_{50} > 10 \mu\text{M}$ in the same assay, demonstrating the specificity for compound 2.

Compound 2 effectively induces cell death in a time- and dose-dependent manner (Figure 9A and Figure 9B). More than 50% of the MDA-MB-231 cancer cells underwent cell death upon treatment with compound 2 at 1 μM for 24 h. Western blot analysis showed that at 1.5 μM , 2 induces robust activation of caspase-3 and cleavage of PARP in the MDA-MB-231 cancer




Figure 9. Analysis of induction of cell death and apoptosis by compound 2 in the MDA-MB-231 cell line. MDA-MB-231 cells were treated with compound 2 at (A) different concentrations for 24 h (B) with 1 μM concentration for different time points. (C) Western blot analysis of caspase processing and cleavage of poly ADP-ribose polymerase (PARP). MDA-MB-231 cells were treated with 1.5 μM concentration of compound 2 for 24 h and cleaved PARP, pro-caspase-3 and cleaved caspase-3 were probed with specific antibodies and actin was used as a loading control.




Figure 10. Induction of cell death by compound 2 in (A) normal-like human breast epithelial MCF-12F cells and (B) primary human normal prostate epithelial cells. Cells were treated with different concentrations of compound 2 for 48 h, and cell viability was determined using the trypan blue exclusion assay.

cells in as little as 12 h (Figure 9C). Hence, compound 2 is a potent activator of caspases and effectively induces apoptosis in the MDA-MB-231 breast cancer cell line.

An ideal anticancer drug should be selectively toxic against cancer cells with minimal toxicity to normal cells. We have evaluated the toxicity against normal or normal-like human epithelial cells using the trypan blue cell death assay. Our data, presented in Figure 10, show that 2 has minimal toxicity against these normal or normal-like human epithelial cells at concentrations as high as 10 μM .

Compound 2 was evaluated for its pharmacokinetic (PK) properties in mice, rats, non-human primates, and dogs. It has an excellent PK profile and good oral bioavailability in each of these four species (Table 1). For example, in non-human primates (NHP), 2 has $C_{\text{max}} = 2.2 \mu\text{g}/\text{mL}$ ($\sim 4 \mu\text{M}$) in the plasma, $T_{1/2} = 5.4$ h, area-under-the-curve (AUC) = 13.5 $\mu\text{g}\cdot\text{h}/\text{mL}$ at 5 mg/kg oral dosing, and oral bioavailability of 42%. In dogs, 2 achieves $C_{\text{max}} = 8.5 \mu\text{g}/\text{mL}$

(17 μM), $T_{1/2} = 27$ h, AUC = 198.2 $\mu\text{M}\cdot\text{h}/\text{mL}$ at 10 mg/kg oral dosing and an oral bioavailability of 55%.

To investigate its mechanism of action in vivo, compound 2 was tested in MDA-MB-231 xenograft tumors in severe combined immune deficiency (SCID) mice. Mice bearing the MDA-MB-231 tumors were given a single oral dose of 2, vehicle control, or intravenous Taxotere (TXT). The levels of cIAP1, procaspase-8, and cleaved poly ADP-ribose polymerase (PARP) in xenograft tissues were analyzed by Western blotting with the results given in Figure 11. At 100 mg/kg, 2 has effectively induced cIAP1 degradation in tumor tissues at the 2 h time-point, and this effect persists for 16 h. It also effectively induces processing of procaspase-8 at the 2 and 6 h time-points, as well as cleavage of the apoptosis marker, PARP, at the 2-h time-point. PARP cleavage reaches a maximum level at the 6-h time point and is still evident after 16 h. In comparison, TXT induces the processing of procaspase-8 but has a minimal effect on cIAP1 degradation and PARP cleavage at the 24 h time-point. Thus, 2 is

Table 1. Pharmacokinetic Properties of Compound 2 in Four Different Species

species	route	dose (mg/kg)	AUC(0–t) (h·μg/mL)	C _{max} (μg/mL)	T _{1/2} (h)	F (%)
mice	iv	10	3.8		3.0	
	po	30	4.3	1.2	2.3	38
rats	iv	5	1.1 ± 0.1		1.4 ± 0.2	
	po	25	2.3 ± 0.7	0.66 ± 0.27	1.8 0.3	45
NHP	iv	2.5	17.9 ± 11.0		6.3 ± 0.4	
	po	5	13.5 ± 7.9	2.2 ± 0.6	5.4 ± 1.0	42
dogs	iv	5	81.6 ± 17.3		16.3 ± 3.8	
	po	10	90.3 ± 23.5	8.5 ± 2.5	27.1 ± 13.7	55




Figure 11. Evaluation of compound 2 on cIAP1, caspase-8 processing, and PARP cleavage in the MDA-MB-231 xenograft tissues. Mice bearing the MDA-MB-231 tumors were treated with a single oral dose of compound 2, intravenous Taxotere (TXT), or intravenous vehicle. cIAP1, XIAP, pro-caspase-8 (Pro-C8), and cleaved PARP (CL-PARP) were examined by Western blotting.

effective in induction of cIAP1 degradation, processing of caspase-8, and PARP cleavage in the MDA-MB-231 xenograft tissues.

Compound 2 was evaluated for its *in vivo* antitumor activity as an oral agent in the MDA-MB-231 xenograft model in mice. In our toxicity evaluation, compound 2 was found to be well tolerated in mice at 200 mg/kg, daily for 5 days a week for 2–3 weeks via oral gavage. In this efficacy experiment, each treatment or control group consisted of eight to nine mice, each mouse bearing one tumor. Treatment started on day 25 when the mean tumor size reached 150 mm³. Compound 2 was given via oral gavage daily, 5 days a week for 2 weeks at 10, 30, and 100 mg/kg. Vehicle alone was administered daily, 5 days a week for 2 weeks, to a control group of animals. TXT was given intravenously at 7.5 mg/kg once a week for 2 weeks. The results, shown in Figure 12, indicate that while 2 has no significant antitumor activity at 10 mg/kg, it strongly inhibits tumor growth at 30 and 100 mg/kg and completely inhibits tumor growth during the treatment with 100 mg/kg. The *T/C* values for 2 at 100 mg/kg on days 36 and 50 are 0.26 and 0.30, respectively, when the control tumors reach 500 and 1100 mm³. Hence, in this model, compound 2 is a highly active agent, according to the National Cancer Institute (NCI) criteria (*T/C* < 0.42). The tumor growth inhibition on day 36 at both 30 and 100 mg/kg is statistically highly significant with *p* of 0.0083 and 0.0012, respectively, compared to the vehicle control group. The positive control, TXT, also achieves a strong antitumor activity in the MDA-MB-231 xenografts, similar to that of 2 at 100 mg/kg, but it causes significant weight loss in animals during the treatment period (*p* = 0.01 at day 36), compared to the vehicle-treated animals. These results indicate that compound 2 is very effective in inhibition of tumor growth in the MDA-MB-231 xenograft model and has minimal toxicity to animals.

To gain further insights into the PK of compound 2 in both plasma and tumor tissues, we performed an analysis with SCID mice bearing the MDA-MB-231 tumors. SCID mice were given a single dose of compound 2 either intravenously (iv) or via oral gavage (po), and the concentration of compound 2 was determined in both




Figure 12. *In vivo* antitumor activity of compound 2 in the MDA-MB-231 xenograft model. Taxotere (TXT) was used as the control: (A) tumor volume; (B) animal weight.

plasma and tumor tissues. The data are shown in Figure 13 and Table 2. At 10 mg/kg iv, 10 mg/kg po, 30 mg/kg po, or 100 mg/kg po dosing, compound 2 achieves C_{max} of 3.0 μg/mL (5.0 μM), 0.9 μg/mL (1.5 μM), 1.2 μg/mL (2.0 μM), and 5.9 (9.9 μM), respectively, and AUC(0–t) of 3.8, 1.2, 4.3, and 17.4 h·μg/mL in the plasma. In comparison, at 10 mg/kg iv, 10 mg/kg po, 30 mg/kg




Figure 13. Analysis of pharmacokinetics of compound **2** in plasma and in tumor tissues in SCID mice bearing the MDA-MB-231 xenograft tumors. Compound **2** was dosed via either intravenously (iv) or oral gavage (po).

Table 2. Pharmacokinetics of Compound **2** in Mice in Plasma and in Tumor Tissues^a

dose (mg/kg) (route)	AUC(0–t) (h·μg/mL)	C _{max} (μg/mL)	T _{max} (h)	T _{1/2} (h)	F (%)
Plasma					
10 (iv)	3.8	3.0		3.0	
10 (po)	1.2	0.9	1	2.4	31
30 (po)	4.3	1.2	2.0	2.3	38
100 (po)	17.4	5.9	0.25	5.4	46
Tumor Tissues					
10 (iv)	8.3	3.6	0.25		
10 (po)	1.1	0.26	1.0		
30 (po)	9.6	2.4	2.0		
100 (po)	57.3	10.8	2.0		

^a Compound **2** was dosed via either intravenously (iv) or oral gavage (po).

po, or 100 mg/kg po dosing, compound **2** achieves C_{max} of 3.6 μg/mL (6.0 μM), 0.26 μg/mL (0.5 μM), 2.4 μg/mL (3.9 μM), and 10.9 μg/mL (18.2 μM), respectively, and AUC(0–t) values of 8.3, 1.1, 9.6, and 57.3 h·μg/mL in the tumor tissues. These data indicate that compound **2** has an excellent tumor tissue penetration. Since compound **2** is effective in inhibition of tumor growth in the MDA-MB-231 xenograft model at 30 mg/kg oral dosing and completely inhibits tumor growth at 100 mg/kg oral dosing, these data support the dose levels and drug exposures needed for compound **2** to achieve strong antitumor activity in vivo.

In summary, we have designed and synthesized compound **2**, a nonpeptidic Smac mimetic. Our data demonstrate that compound **2** binds to XIAP, cIAP1, and cIAP2 with nanomolar affinities and is a potent antagonist against these IAP proteins. It also achieves an excellent oral bioavailability in rodents and non-rodents and has good aqueous solubility (>50 mg/mL). As a single agent, it effectively inhibits cancer cell growth in a subset of human cancer cell lines and is highly effective in inhibition of tumor growth with oral dosing while causing no signs of toxicity in mice. On the basis of these data, it was selected for further evaluation as a candidate for clinical development. Investigational new drug (IND) enabling studies under FDA guidelines were conducted. These IND-enabling studies demonstrated that compound **2** has good metabolic stability, has a minimal

interaction with cytochrome P450s, does not inhibit hERG ion channel at concentrations as high as 30 μM, and is well tolerated in dogs (data not shown). Taken together, compound **2** represents an excellent compound for clinical development. Compound **2** (renamed AT-406 by Ascenta Therapeutics) is now being evaluated in phase I clinical trials as a new therapy for the treatment of solid and hematological human tumors.

EXPERIMENTAL SECTION

Chemistry. *General Methods.* ¹H NMR spectra were measured at 300 MHz. ¹H chemical shifts are reported with CHCl₃ (7.27 ppm), DHO (4.79 ppm), and CD₃OH (3.34 ppm) as internal standards. Final products were purified by HPLC on a C18 reverse phase semipreparative column with solvent A (0.1% of TFA in water) and solvent B (0.1% of TFA in CH₃CN) as eluents, and the purity of the final products was checked by analytical HPLC using the C18 reverse phase column to be over >95%.

tert-Butyl ((5S,8S,10aR)-8-(Benzhydrylcarbamoyl)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocin-5-yl)carbamate (8). Isovaleryl chloride (0.2 mL) and *N,N*-diisopropylethylamine (0.4 mL) were added to a solution of **6** (340 mg, 1 mmol) in CH₂Cl₂ (20 mL). The solution was stirred at room temperature for 3 h and then concentrated. The residue was purified by chromatography to give an amide. Then **2** N

LiOH solution (2.0 mL) was added to a solution of this amide in 1,4-dioxane (3.0 mL). After TLC showed all of the amide had been consumed, the mixture was neutralized with 1 N HCl to pH 5 and then extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over Na₂SO₄ and then concentrated to give the acid **7** (340 mg, 82% over two steps), which was used directly, without purification, in the next step. To a solution of **7** (105 mg, 0.25 mmol) in CH₂Cl₂ (10 mL) were added aminodiphenylmethane (55 mg, 0.3 mmol), EDC (58 mg, 0.3 mmol), HOBt (45 mg, 0.33 mmol), and *N,N*-diisopropylethylamine (0.5 mL) at 0 °C. The mixture was stirred at room temperature for 6 h and then concentrated. The residue was purified by chromatography to give **8** (120 mg, 82%). ¹H NMR (CDCl₃): δ 7.70 (brd, *J* = 7.0 Hz, 1H), 7.35–7.16 (m, 10H), 6.25 (d, *J* = 7.5 Hz, 1H), 5.90 (brd, *J* = 7.0 Hz, 1H), 4.70 (m, 1H), 4.45 (m, 1H), 4.08–3.70 (m, 3H), 2.80–2.50 (m, 3H), 2.42 (m, 1H), 2.30–1.50 (m, 7H), 1.47 (brs, 9H), 1.02 (m, 6H). ESI-MS: *m/z* 577.3 (M + H)⁺.

(5*S*,8*S*,10*aR*)-*N*-Benzhydryl-5-((*S*)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-*a*][1,5]diazocine-8-carboxamide (**2**). HCl (4 N in 1,4-dioxane, 1 mL) was added to a solution of **8** (58 mg, 0.1 mmol) in MeOH (10 mL). The solution was stirred at room temperature overnight and then concentrated to give an ammonium salt. To a mixture of this salt in CH₂Cl₂ (10 mL) was added *L*-*N*-Boc-*N*-methylalanine (30 mg, 0.15 mmol), EDC (29 mg, 0.15 mmol), HOBt (22 mg, 0.16 mmol), and *N,N*-diisopropylethylamine (0.3 mL) at 0 °C. The mixture was stirred at room temperature for 6 h and then concentrated. The residue was purified by chromatography to furnish an amide. To a solution of this amide in 5 mL of MeOH was added HCl solution (4 N in 1,4-dioxane, 1 mL). The solution was stirred at room temperature overnight and then concentrated to give crude product which was purified by HPLC to give pure compound **2** (salt with TFA, 48 mg, 74% over three steps). The gradient ran from 70% A and 30% B to 50% A and 50% B in 30 min. The purity was determined by reverse analytical HPLC to be over 95%. ¹H NMR (CD₃OD, 300 M Hz): δ 8.97 (d, *J* = 7.5 Hz, 1H), 7.38–7.25 (m, 10H), 6.16 (d, *J* = 7.5 Hz, 1H), 4.80 (m, 1H), 4.58 (m, 1H), 4.25 (m, 1H), 3.96 (m, 3H), 3.47 (m, 1H), 2.72 (s, 3H), 2.49 (d, *J* = 7.2 Hz, 2H), 2.37–2.32 (m, 1H), 2.15–2.00 (m, 6H), 1.84–1.80 (m, 1H), 1.56 (d, *J* = 5.4 Hz, 3H), 1.00 (d, *J* = 6.0 Hz, 6H). ESI-MS: *m/z* 562.3 (M + H)⁺.

(5*S*,8*S*,10*aR*)-5-((*S*)-3-(1*H*-indol-3-yl)-2-(methylamino)propanamido)-*N*-benzhydryl-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-*a*][1,5]diazocine-8-carboxamide (**3**). HCl (4 N in 1,4-dioxane, 1 mL) was added to a solution of **8** (58 mg, 0.1 mmol) in MeOH (10 mL). The solution was stirred at room temperature overnight and then concentrated to give an ammonium salt. To a mixture of this salt in 10 mL of CH₂Cl₂ was added *L*-*N*α-Boc-*N*α-methyltryptophan (48 mg, 0.15 mmol), EDC (30 mg, 0.15 mmol), HOBt (22 mg, 0.16 mmol), and *N,N*-diisopropylethylamine (0.3 mL) at 0 °C. The mixture was stirred at room temperature for 6 h and then concentrated. The residue was purified by chromatography to furnish an amide. To a solution of this amide in 5 mL of MeOH was added HCl (4 N in 1,4-dioxane, 1 mL). The solution was stirred at room temperature overnight and then concentrated to give crude product which was purified by HPLC to give **3** (salt with TFA, 49 mg, 63% over three steps). The gradient ran from 70% A and 30% B to 40% A and 60% B in 30 min. The purity was determined by reverse analytical HPLC to be >95%. ¹H NMR (CD₃OD, 300 M Hz): δ 8.88 (d, *J* = 8.4 Hz, 1H), 7.33–7.08 (m, 13H), 6.95 (m, 2H), 6.10 (m, 1H), 4.40 (m, 1H), 4.34 (m, 1H), 4.27 (m, 1H), 4.23 (m, 1H), 3.97 (m, 2H), 3.83 (m, 2H), 3.44 (m, 1H), 3.10 (m, 2H), 2.73 (2*s*, 3H), 2.52 (m, 2H), 2.36 (m, 1H), 2.18–1.72 (m, 6H), 1.00 (m, 6H). ESI-MS: *m/z* 677.4 (M + H)⁺.

tert-Butyl Methyl((*S*)-1-(((5*S*,8*S*,10*aR*)-3-(3-methylbutanoyl)-6-oxo-8-(((*R*)-1-phenylprop-2-yn-1-yl)carbamoyl)decahydropyrrolo[1,2-*a*][1,5]diazocin-5-yl)amino)-1-oxopropan-2-yl)carbamate (**10**). *S*-1-Phenylprop-2-yn-1-amine (79 mg, 0.6 mmol), EDC (116 mg, 0.6 mmol), HOBt (80 mg, 0.6 mmol), and *N,N*-diisopropylethylamine (1 mL) were added to a solution of **7** (205 mg, 0.5 mmol) in CH₂Cl₂ (15 mL) at 0 °C. The mixture was

stirred at room temperature for 6 h and then concentrated. The residue was purified by chromatography to give an amide. To a solution of this amide in MeOH (15 mL) was added HCl solution (4 N in 1,4-dioxane, 2 mL). The solution was stirred at room temperature overnight and then concentrated to give an ammonium salt. To a mixture of this salt in CH₂Cl₂ (20 mL) was added *L*-*N*-Boc-*N*-methylalanine (124 mg, 0.6 mmol), EDC (120 mg, 0.6 mmol), HOBt (83 mg, 0.6 mmol), and *N,N*-diisopropylethylamine (1 mL) at 0 °C. The mixture was stirred at room temperature for 6 h and then concentrated. The residue was purified by chromatography to give **11** (210 mg, 69% over three steps). ¹H NMR (300 MHz, CDCl₃, TMS): δ 7.58 (m, 1H), 7.54–7.49 (m, 2H), 7.36–7.20 (m, 4H), 5.95 (dd, *J* = 8.5, 2.4 Hz, 1H), 4.70 (m, 1H), 4.60–4.45 (m, 2H), 3.95 (m, 1H), 3.92–3.80 (m, 2H), 2.79 (s, 3H), 2.70–2.35 (m, 5H), 2.35–1.75 (m, 7H), 1.50 (brs, 9H), 1.33 (d, *J* = 7.2 Hz, 3H), 1.05–0.95 (m, 6H). ESI-MS: *m/z* 610.3 (M + H)⁺.

(5*S*,8*S*,10*aR*)-5-((*S*)-2-(Methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxo-*N*-((*S*)-1-(10-(6-(5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamido)hexanamido)decyl)-1*H*-1,2,3-triazol-4-yl)(phenyl)methyl)decahydropyrrolo[1,2-*a*][1,5]diazocine-8-carboxamide (**4**). *Z*-6-Aminohexanoic acid (790 mg, 3 mmol), EDC (590 mg, 3 mmol), HOBt (395 mg, 3 mmol), and triethylamine (2 mL) were added to a solution of 10-amino-1-decanol (**9**, 520 mg, 3 mmol) in CH₂Cl₂ (15 mL) at 0 °C. The mixture was stirred at room temperature for 6 h and then concentrated. The residue was purified by chromatography to furnish an amide. Methanesulfonyl chloride (0.3 mL) and triethylamine (1 mL) in CH₂Cl₂ (20 mL) were added to a solution of this amide at 0 °C. The solution was stirred at room temperature for 6 h and then concentrated. The residue was purified by chromatography to yield a mesylate. Sodium azide (200 mg) was added to a solution of this mesylate in DMF (10 mL), and the mixture was stirred at 110 °C overnight and then partitioned between EtOAc (50 mL) and brine (30 mL). The organic layer was dried over Na₂SO₄ and then concentrated. The residue was purified by chromatography to provide **10** (650 mg, 49% over three steps). CuSO₄ (25 mg, 0.1 mmol) and sodium *L*-ascorbate (100 mg, 0.5 mmol) in water (5 mL) were added to a solution of **10** (122 mg, 0.2 mmol) and **9** (90 mg, 0.2 mmol) in acetonitrile (3 mL) and *tert*-butanol (3 mL). The mixture was stirred at room temperature overnight and then partitioned between EtOAc (30 mL) and brine (20 mL). The organic layer was dried over Na₂SO₄ and then concentrated. The residue was purified by chromatography to give a triazole which, mixed with 10% Pd–C (100 mg) in MeOH (20 mL), was stirred under H₂ overnight and then filtered through Celite. The filtration was concentrated to yield an amine. To a solution of this amine in CH₂Cl₂ (20 mL) was added (+)-biotin *N*-hydroxysuccinimide ester (78 mg, 0.2 mmol) and *N,N*-diisopropylethylamine (0.5 mL). The solution was stirred at room temperature overnight and then concentrated to give a residue which was purified by chromatography to afford a biotinylated amide. To a solution of this amide in MeOH (10 mL) was added HCl solution (4 N in 1,4-dioxane, 2 mL). The mixture was stirred overnight and then concentrated to furnish a crude product which was purified by a semipreparative HPLC using a reverse phase C18 column to give pure compound **4** (salt with TFA, 98 mg, 43% over four steps). The gradient ran from 70% of A and 30% of B to 40% of A and 60% of B in 30 min. The purity of the compound was determined by an analytical HPLC using a reverse phase C18 column to be over 95%. ¹H NMR (D₂O): δ 7.70 (brs, 1H), 7.35–7.05 (m, 5H), 6.05 (brs, 1H), 4.70 (m, 1H), 4.50–4.30 (m, 2H), 4.30–4.05 (m, 3H), 4.05–3.60 (m, 2H), 3.60–2.80 (m, 5H), 2.80–2.50 (m, 6H), 2.40–1.05 (m, 44H), 0.80 (m, 6H). ESI-MS: *m/z* 1047.6 (M + H)⁺.

2-(6-Hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-((10-(4-((*S*)-((5*S*,8*S*,10*aR*)-5-((*S*)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-*a*][1,5]diazocine-8-carboxamido)(phenyl)methyl)-1*H*-1,2,3-triazol-1-yl)decyl)carbamoyl)benzoic Acid (**5**). Benzyl chloroformate (0.5 mL) and triethylamine (2 mL) were added to a solution of 10-amino-1-decanol (**10**, 520 mg, 3 mmol) in CH₂Cl₂ (15 mL) at 0 °C. The mixture was stirred at room temperature for 6 h and then concentrated. The residue was purified by chromatography to furnish a carbamate. Methanesulfonyl chloride (0.5 mL) was added dropwise at 0 °C to a solution of this

carbamate in CH_2Cl_2 (20 mL) with triethylamine (1 mL). The solution was stirred at room temperature for 6 h and then concentrated. The residue was purified by chromatography to yield a mesylate. Sodium azide (300 mg) was added to a solution of this mesylate in DMF (10 mL). The mixture was stirred at 110 °C overnight and then partitioned between EtOAc (50 mL) and brine (30 mL). The organic layer was dried over Na_2SO_4 and then concentrated. The residue was purified by chromatography to provide **12** (650 mg, 66% over three steps). A mixture of CuSO_4 (25 mg, 0.1 mmol) and sodium L-ascorbate (100 mg, 0.5 mmol) in water (5 mL) was added to a solution of **11** (122 mg, 0.2 mmol) and **12** (66 mg, 0.2 mmol) in acetonitrile (3 mL) and *tert*-butanol (3 mL). The mixture was stirred at room temperature overnight and then partitioned between EtOAc (30 mL) and brine (20 mL). The organic layer was dried over Na_2SO_4 and then concentrated. The residue was purified by chromatography to give a triazole. A mixture of this triazole and 100 mg of 10% Pd–C in MeOH (20 mL) was stirred under H_2 overnight and then filtered through Celite. The filtration was concentrated to yield an amine. To a solution of this amine in CH_2Cl_2 (20 mL) was added 5-carboxyfluorescein *N*-succinimidyl ester (95 mg, 0.2 mmol) and *N,N*-diisopropylethylamine (0.5 mL). The solution was stirred at room temperature overnight and then concentrated. The residue was purified by chromatography to afford an amide. To a solution of this amide in MeOH (10 mL) was added HCl (4 N in 1,4-dioxane, 2 mL). The mixture was stirred overnight and then concentrated to furnish a crude product which was purified by semipreparative HPLC using a reverse phase C18 column to give compound **5** (salt with TFA, 72 mg, 34% over four steps). The gradient ran from 70% of A and 30% of B to 40% of A and 60% of B in 30 min. The purity of the compound was determined by analytical HPLC using a reverse phase C18 column to be over 95%. ^1H NMR (CD_3OD , 300 MHz): δ 8.48 (s, 1H), 8.22 (m, 1H), 7.70 (s, 1H), 7.50–7.20 (m, 5H), 6.75 (brs, 2H), 6.70–6.50 (m, 4H), 6.30 (brs, 1H), 4.70 (m, 1H), 4.65–4.50 (m, 2H), 4.40–4.30 (m, 2H), 4.30–4.15 (m, 2H), 4.05–3.80 (m, 3H), 3.50–3.40 (m, 2H), 2.70 (brs, 3H), 2.52–2.01 (m, 7H), 2.01–1.60 (m, 7H), 1.60–1.50 (m, 3H), 1.50–1.20 (m, 11H), 0.95 (m, 6H). ESI MS: m/z 1066.5 (M + H) $^+$.

Computational Docking Simulation. The crystal structure of XIAP BIR3 in a complex with the Smac protein²³ (PDB code 1G73) was used to predict the binding models of XIAP BIR3 bound to compound **2**. The binding pose of compound **2** with XIAP BIR3 was predicted with the GOLD program (version 3.1.1).^{46,47} In the docking simulation, the center of the binding site was set at Thr308 of XIAP BIR3 and the radius of the binding site was defined as 13 Å, sufficient to cover all the binding pockets. For each genetic algorithm (GA) run, a maximum of 200 000 operations were performed on a population of 5 islands of 100 individuals. Operator weights for crossover, mutation, and migration were set to 95, 95, and 10, respectively. The docking simulation was terminated after 20 runs for compound **2**. GoldScore, implemented in Gold, was used as the fitness function to evaluate the docked conformations. The 20 conformations ranked highest by each fitness function were saved for analysis of the predicted docking modes. The docking protocol was validated using a series of Smac mimetics.⁴⁵ The predicted binding pose of compound **2** shown in Figure 2 is the highest ranked conformation from the docking simulations.

Fluorescence Polarization Based Assays for XIAP, cIAP1, and cIAP2 BIR3 Proteins. Sensitive and quantitative fluorescence polarization (FP) based assays were used to determine the binding affinities of our designed Smac mimetics to XIAP BIR3, cIAP1 BIR3, and cIAP2 BIR3 proteins.

Human XIAP BIR3-only (residues 241–356) was cloned into a pET28 vector (Novagen) containing an N-terminal 6× His tag. Protein was produced in *E. coli* BL21(DE3) cells grown at 37 °C in 2× YT containing kanamycin to an OD_{600} of 0.6. Protein expression was induced by 0.4 mM IPTG at 27 °C for 4 h. Cells were lysed by sonication in buffer containing Tris, pH 7.5 (50 mM), NaCl (200 mM), ZnAc (50 μM), 0.1% βME , and leupeptin/aprotin protease inhibitors. Protein was purified from

the soluble fraction using Ni-NTA resin (QIAGEN) followed by gel filtration on a Superdex 75 column in Tris, pH 7.5 (20 mM), NaCl (200 mM), ZnAc (50 μM), and dithiothreitol (DTT, 1 mM). After purification, DTT was added to a final concentration of 10 mM. Human cIAP1 BIR3-only (residues 253–363) and cIAP2 BIR3-only (residues 238–349) were cloned into pHis-TEV vector, produced, and purified using the same method as for the XIAP BIR3 protein.

The fluorescently tagged compound **5** was employed to develop a set of new FP assays for determination of the binding affinities of our designed Smac mimetics to XIAP, cIAP-1, and cIAP-2 BIR3 proteins. The K_d value of compound **5** to each IAP protein was determined by titration experiments using a fixed concentration of compound **5** and different concentrations of the protein up to full saturation. Fluorescence polarization values were measured using an Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, NC) in Microfluor 2 96-well, black, round-bottom plates (Thermo Scientific). To each well, compound **5** (2, 1, and 1 nM for experiments with XIAP BIR3, cIAP-1 BIR3, and cIAP-2 BIR3, respectively) and different concentrations of the protein were added to a final volume of 125 μL in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 $\mu\text{g}/\text{mL}$ bovine γ -globulin, 0.02% sodium azide, Invitrogen, with 4% DMSO). Plates were mixed and incubated at room temperature for 2–3 h with gentle shaking. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (K_d) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, CA).

In competitive binding experiments for XIAP3 BIR3, a tested compound was incubated with 20 nM XIAP BIR3 protein and 2 nM compound **5** in the assay buffer (100 mM potassium phosphate, pH 7.5; 100 $\mu\text{g}/\text{mL}$ bovine gamma globulin; 0.02% sodium azide, Invitrogen). In competitive binding experiments for cIAP1 BIR3 protein, 3 nM protein and 1 nM compound **5** were used. In competitive binding experiments for cIAP2 BIR3, 5 nM protein and 1 nM compound **5** were used.

For each competitive binding experiment, polarization values were measured after 2–3 h of incubation using an Infinite M-1000 plate reader. The IC_{50} value, the inhibitor concentration at which 50% of the bound tracer was displaced, was determined from the plot using non-linear least-squares analysis. Curve fitting was performed using the PRISM software (GraphPad Software, Inc., San Diego, CA). A K_i value for each compound was calculated based upon the IC_{50} using a previously reported algorithm and the associated computer program.⁴⁸

Cell-Free Functional Assay against XIAP BIR3 Protein. MDA-MB-231 cell lysates were prepared by solubilizing cells in ice cold buffer containing KCl (50 mM), EGTA (5 mM), MgCl_2 (2 mM), DTT (1 mM), 0.2% CHAPS, and HEPES (50 mM, pH 7.5), containing cocktail protease inhibitors, incubating on ice for 10 min, then freezing in liquid nitrogen. Cytochrome *c* and dATP were added to the cell lysates, which were then incubated at 30 °C in a water bath for 60 min to activate caspase-9. Addition of recombinant XIAP BIR3 protein dose-dependently suppressed the activity of caspase-9. Different concentrations of a tested Smac mimetic (1 nM to 100 μM) were added to determine the restoration of the activity of these caspases.

For determination of caspase-9 activity, the caspase-9 substrate Z-LEHD-AFC (25 μM) (BioVision Inc.) was added. Fluorescence detection of substrate cleavage by caspase-9 for the substrate was carried out on an ULTRA READER using an excitation wavelength of 400 nm and an emission wavelength of 505 nm. The reaction was monitored for 1–2 h.

Biotin–Streptavidin Pull-Down Experiment. MDA-MB-231 cells were lysed in NETN buffer (50 mM Tris (pH 8), 1 mM EDTA, 150 mM NaCl, 0.5% NP-40). Lysates were precleared with streptavidin–agarose beads to remove nonspecifically adsorbed proteins. Precleared lysates were incubated with biotinylated compound **4** for 1 h,

followed by incubation with new streptavidin–agarose beads for 2 h to pull-down proteins bound to compound 4. Beads were washed with NETN buffer, and proteins were eluted by boiling in SDS-PAGE sample buffer and analyzed by Western blotting using specific antibodies. DMSO alone was used as a control for nonspecific pull-down. In the competition experiments, precleared cell lysates were incubated with different concentrations of compound 2 for 30 min, followed by incubation with biotinylated 4 and streptavidin–agarose beads.

Cell Growth Inhibition and Cell-Death Assays. The MDA-MB-231 breast cancer and SK-OV-3 ovarian cancer cell lines were purchased from the American Type Culture Collection (ATCC). Cells were seeded in 96-well flat bottom cell culture plates at a density of $(3-4) \times 10^3$ cells/well with compounds and incubated for 4 days. The rate of cell growth inhibition after treatment with different concentrations of the inhibitors was determined by assaying with (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium monosodium salt (WST-8; Dojindo Molecular Technologies Inc., Gaithersburg, MD). WST-8 was added to each well to a final concentration of 10%, and then the plates were incubated at 37 °C for 2–3 h. The absorbance of the samples was measured at 450 nm using a TECAN ULTRA reader. Concentration of the compounds that inhibited cell growth by 50% (IC_{50}) was calculated by comparing absorbance in the untreated cells and the cells treated with the compounds.

A trypan blue exclusion assay was used for determination of cell viability. Cells were treated with compounds at different concentrations and time-points. Cell viability was determined using the trypan blue exclusion assay. Blue cells or morphologically unhealthy cells were scored as dead cells. At least 100 cells from each treatment, performed in triplicate, were counted.

Western Blot Analysis. Cells and xenograft tumor tissues were lysed using radioimmunoprecipitation assay (RIPA) lysis buffer (PBS containing 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate [SDS]) supplemented with 1 μ M phenylmethylsulfonyl fluoride and 1 protease inhibitor cocktail tablet per 10 mL on ice for 20 min, and lysates were then cleared by centrifugation prior to protein concentration determination using the Bio-Rad protein assay kit according to the manufacturer's instructions. Proteins were electrophoresed onto 18% SDS-PAGE gels (Invitrogen, Grand Island, NY) and transferred to PVDF membranes. Following blocking in 5% milk, membranes were incubated with a specific primary antibody, washed, and incubated with horseradish peroxidase linked secondary antibody (Amersham, Piscataway, NJ). The signals were visualized with the chemiluminescent HRP antibody detection reagent (Denville Scientific, Metuchen, NJ). When indicated, the blots were stripped and reprobed with a different antibody.

The following primary antibodies were used in the study: anti-cleaved-caspase 8, anti-XIAP, anti-PARP (Cell Signaling Technology, Beverly, MA), anti-cIAP1 (from R&D), anti-cIAP2 (R&D), anti-caspase-3, anti-caspase-9, and anti-procaspase-8 (Stressgen Biotechnologies, Victoria, Canada) for Western blot analysis.

In Vivo Pharmacodynamic (PD) Studies. For in vivo PD studies, the MDA-MB-231 xenograft tumor model was employed. To develop xenograft tumors, 5×10^6 MDA-MB-231 cancer cells with Matrigel were injected subcutaneously on the dorsal side of the severe combined immunodeficient mice (SCID mice from Charles River), one tumor per mouse. Mice bearing MDA-MB-231 xenograft tumors were administered with a single dose of compound 2 in its HCl salt form at 100 mg/kg via oral gavage, Taxotere at 7.5 mg/kg intravenously, or vehicle control. Tumor tissues were harvested at indicated time points. Tumor tissues were analyzed using Western blotting to examine levels of cIAP1 and XIAP, caspase-8 processing, and PARP cleavage in tumor tissues. All animal experiments were performed under the guidelines of the University of Michigan Committee for Use and Care of Animals.

In Vivo Pharmacokinetic Studies in Plasma and MDA-MB-231 Tumor Tissues in SCID Mice. To develop xenograft tumors, 5×10^6 MDA-MB-231 cancer cells with Matrigel were injected subcutaneously on the dorsal side of the severe combined immunodeficient

mice (SCID mice from Charles River), two tumors (left and right sides) per mouse. Mice bearing MDA-MB-231 xenograft tumors were administered with a single dose of compound 2 in its HCl salt form at 100 mg/kg via oral gavage. Blood and tumor samples were collected from each mouse by terminal cardiac puncture at 0.25, 0.5, 1, 2, 4, 6, 8, 24 h postdose. Samples were taken from three mice at each time point. Blood samples were collected into potassium heparin treated tubes and centrifuged at 2000g and 4 °C for 10 min. Plasma was collected and stored at –80 °C prior to analysis. Isolated tumor tissues were immediately frozen and ground with a mortar and pestle in liquid nitrogen, then stored at –80 °C until analysis.

The quantitative LC/MS/MS analyses were conducted using an Agilent 1200 HPLC system coupled to an API 3200 mass spectrometer (Applied Biosystems, MDS Sciex Toronto, Canada) equipped with an API electrospray ionization (ESI) source. Mobile phase A and mobile phase B were water and methanol, and both contained 5 mM ammonium acetate and 0.1% formic acid (v/v). The flow gradient was initially 90:10 v/v of A/B for 2 min, linearly ramped to 0:100 over 4 min, held at 0:100 for 2 min, and then returned to 90:10 over 0.1 min. This condition was held for a further 5 min prior to the injection of another sample. The mass spectrometer was operated in ESI positive ion mode, and detection of the ions was performed in the multiple reaction monitoring (MRM) mode, monitoring the transition of m/z 562.3 precursor ion $[M + H]^+$ to the m/z 167.1 product ion for compound 2 and m/z 610.2 precursor ion $[M + H]^+$ to the m/z 167.1 product ion for IS using an analogue of compound 2 (SM-408). The ion spray voltage was set at 5500 V. Ionization temperature was set at 700 °C. The instrument parameters, curtain gas, gas 1, and gas 2 (auxiliary gas), were set at 20, 60 and 60, respectively. Compounds parameters, declustering potential (DP), collision energy (CE), entrance potential (EP), collision entrance energy (CEP), and collision exit potential (CXP), were 61, 45, 5, 26, 4 V and 61, 45, 9, 27.3, 4 V for compound 2 and the IS, respectively. Data acquisition and quantitation were performed using Analyst software, version 1.4.2 (Applied Biosystems, MDS Sciex Toronto, Canada).

Compound 2 was dissolved in 50% acetonitrile, and the IS solution was prepared by dissolving the IS in acetonitrile to yield a final concentration of 100 ng/mL. Plasma samples were prepared by mixing 50 μ L of plasma with 10 μ L of 50% acetonitrile and 140 μ L of IS solution. The solution was vortexed for 1 min at high speed and centrifuged at 13 000 rpm for 10 min to precipitate protein. The clear supernatants were transferred to vial inserts for LC/MS/MS analysis. Ten calibration standard solutions for constructing standard curve were prepared by mixing 10 μ L of compound 2 at 2.5, 5, 25, 50, 250, 500, 2500, 5000, 10000, 25000 ng/mL with 50 μ L of blank plasma and 140 μ L of IS solution. To prepare tumor samples, about 60–80 mg of ground tumor powder was weighed and mixed with PBS to obtain final concentrations (w/v) of 200 mg/mL. Samples were homogenized using a tissue homogenizer (Tissuemiser homogenizer, Fisher Scientific) for 20 s. Then 10 μ L of 50% acetonitrile and 90 μ L IS solution were added and vortexed for 1 min at high speed. The tubes were centrifuged at 13 000 rpm for 10 min to precipitate protein. The clear supernatants were transferred to vial inserts for analysis. Calibration standard solutions for constructing standard curve were prepared by mixing 10 μ L of compound 2 at 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000 ng/mL with 20 μ L of blank tumor homogenate and 90 μ L of IS solution. Plasma and tumor concentration–time data were analyzed using noncompartmental pharmacokinetic methods with the WinNolin software package (Pharsight Corporation, CA, U.S.). The PK experiments were performed under the guidelines of the University of Michigan Committee for Use and Care of Animals.

In Vivo Antitumor Efficacy Study. SCID mice (8–10 per group) bearing MDA-MB-231 xenograft tumors were treated with different doses of compound 2, or 7.5 mg/kg of Taxotere or vehicle control daily, 5 days a week for 2 weeks. Tumor sizes and animal weights were measured 3 times a week during the treatment and twice a week

after the treatment. Data are presented as mean tumor volumes \pm SEM. Statistical analyses were performed by two-way ANOVA and unpaired two-tailed *t* test, using Prism (version 4.0, GraphPad, La Jolla, CA). *P* < 0.05 was considered statistically significant. The efficacy experiment was performed under the guidelines of the University of Michigan Committee for Use and Care of Animals.

Pharmacokinetics of Compound 2 in Rats, Dogs, and Non-Human Primates. Pharmacokinetic (PK) studies in male Sprague–Dawley rats, beagle dogs, and cynomolgus monkeys (non-human primates) were performed by the Division of Pharmacokinetics and Metabolism, Shanghai Medicilon Inc., Shanghai 201203, P. R. China.

Compound 2 in its hydrochloride salt form was used in pharmacokinetic (PK) evaluations and was dissolved in saline to yield a final concentration at 25 mg/mL (pH \approx 7). The solution was administered to animals on preparation. The concentration of compound 2 in dosing solution was confirmed by HPLC.

For PK studies in rats, dogs, and monkeys, animals were randomly assigned to the treatment groups and were carotid cannulated before the PK studies. The LC system comprised an Agilent (Agilent Technologies Inc., U.S.) liquid chromatograph equipped with an isocratic pump (1100 series), an autosampler (1100 series), and a degasser (1100 series). Mass spectrometric analysis was performed using an API3000 (triple–quadruple) instrument from AB Inc. (Canada) with an ESI interface. The data acquisition and control system were created using Analyst 1.4 software from ABI Inc. The concentrations in plasma below the limit of quantitation (LOQ = 5 ng/mL) were designated as zero. The pharmacokinetic data analysis was performed using noncompartmental analysis. Oral bioavailability was calculated as $F(\%) = \{[\text{dose (oral)} \times \text{AUC}(0-\infty) (\text{oral})] / [\text{dose (iv)} \times \text{AUC}(0-\infty) (\text{iv})]\} \times 100$.

AUTHOR INFORMATION

Corresponding Author

*Phone: +1 734 6150362. Fax: +1 734 6479647. E-mail: shaomeng@umich.edu.

Present Addresses

[†]Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou 510663, China.

[#]Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, National Institutes of Health, 5625 Fishers Lane, Bethesda, Maryland 20892, United States.

Author Contributions

^{||}These authors contributed equally.

ACKNOWLEDGMENT

We are grateful for the financial support from the Breast Cancer Research Foundation, the National Cancer Institute (Grant R01CA109025), Ascenta Therapeutics, and University of Michigan Cancer Center Core grant from the National Cancer Institute (Grant P30CA046592). The authors thank Dr. G. W. A. Milne for his critical reading of the manuscript and many useful suggestions and Karen Kreutzer for her excellent secretarial assistance.

REFERENCES

- (1) Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. *Nature* **2000**, *407*, 810–816.
- (2) Ponder, B. A. Cancer genetics. *Nature* **2001**, *411*, 336–341.
- (3) Lowe, S. W.; Lin, A. W. Apoptosis in cancer. *Carcinogenesis* **2000**, *21*, 485–495.

- (4) Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. *Cell* **2000**, *100*, 57–70.
- (5) Salvesen, G. S.; Duckett, C. S. Apoptosis: IAP proteins: blocking the road to death's door. *Nat. Rev. Mol. Cell Biol.* **2002**, *3*, 401–410.
- (6) Deveraux, Q. L.; Reed, J. C. IAP family proteins—suppressors of apoptosis. *Genes Dev.* **1999**, *13*, 239–252.
- (7) Holcik, M.; Gibson, H.; Korneluk, R. G. XIAP: apoptotic brake and promising therapeutic target. *Apoptosis* **2001**, *6*, 253–261.
- (8) Shiozaki, E. N.; Shi, Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. *Trends Biochem. Sci.* **2004**, *29*, 486–494.
- (9) Srinivasula, S. M.; Ashwell, J. D. IAPs: what's in a name? *Mol Cell* **2008**, *30*, 123–135.
- (10) Gyrd-Hansen, M.; Meier, P. IAPs: from caspase inhibitors to modulators of NF- κ B, inflammation and cancer. *Nat. Rev. Cancer* **2010**, *10*, 561–74.
- (11) Mehrotra, S.; Languino, L. R.; Raskett, C. M.; Mercurio, A. M.; Dohi, T.; Altieri, D. C. IAP regulation of metastasis. *Cancer Cell* **2010**, *17*, 53–64.
- (12) LaCasse, E. C.; Mahoney, D. J.; Cheung, H. H.; Plenchette, S.; Baird, S.; Korneluk, R. G. IAP-targeted therapies for cancer. *Oncogene* **2008**, *27*, 6252–6275.
- (13) Hunter, A. M.; LaCasse, E. C.; Korneluk, R. G. The inhibitors of apoptosis (IAPs) as cancer targets. *Apoptosis* **2007**, *12*, 1543–1568.
- (14) Vucic, D.; Fairbrother, W. J. The inhibitor of apoptosis proteins as therapeutic targets in cancer. *Clin. Cancer Res.* **2007**, *13*, 5995–6000.
- (15) Srinivasula, S. M.; Hegde, R.; Saleh, A.; Datta, P.; Shiozaki, E.; Chai, J.; Lee, R. A.; Robbins, P. D.; Fernandes-Alnemri, T.; Shi, Y.; Alnemri, E. S. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. *Nature* **2001**, *410*, 112–116.
- (16) Shiozaki, E. N.; Chai, J.; Rigotti, D. J.; Riedl, S. J.; Li, P.; Srinivasula, S. M.; Alnemri, E. S.; Fairman, R.; Shi, Y. Mechanism of XIAP-mediated inhibition of caspase-9. *Mol. Cell* **2003**, *11*, 519–527.
- (17) Chai, J.; Shiozaki, E.; Srinivasula, S. M.; Wu, Q.; Datta, P.; Alnemri, E. S.; Shi, Y. Structural basis of caspase-7 inhibition by XIAP. *Cell* **2001**, *104*, 769–780.
- (18) Huang, Y.; Park, Y. C.; Rich, R. L.; Segal, D.; Myszka, D. G.; Wu, H. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. *Cell* **2001**, *104*, 781–790.
- (19) Riedl, S. J.; Renatus, M.; Schwarzenbacher, R.; Zhou, Q.; Sun, C.; Fesik, S. W.; Liddington, R. C.; Salvesen, G. S. Structural basis for the inhibition of caspase-3 by XIAP. *Cell* **2001**, *104*, 791–800.
- (20) Rothe, M.; Pan, M. G.; Henzel, W. J.; Ayres, T. M.; Goeddel, D. V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. *Cell* **1995**, *83*, 1243–1252.
- (21) Du, C.; Fang, M.; Li, Y.; Wang, X. Smac, a mitochondrial protein that promotes cytochrome *c*-dependent caspase activation by eliminating IAP inhibition. *Cell* **2000**, *102*, 33–42.
- (22) Verhagen, A. M.; Ekert, P. G.; Pakusch, M.; Silke, J.; Connolly, L. M.; Reid, G. E.; Moritz, R. L.; Simpson, R. J.; Vaux, D. L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell* **2000**, *102*, 43–53.
- (23) Chai, J.; Du, C.; Wu, J. W.; Kyin, S.; Wang, X.; Shi, Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. *Nature* **2000**, *406*, 855–862.
- (24) Liu, Z.; Sun, C.; Olejniczak, E. T.; Meadows, R. P.; Betz, S. F.; Oost, T.; Herrmann, J.; Wu, J. C.; Fesik, S. W. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. *Nature* **2000**, *408*, 1004–1008.
- (25) Huang, Y.; Rich, R. L.; Myszka, D. G.; Wu, H. Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac. *J. Biol. Chem.* **2003**, *278*, 49517–49522.
- (26) Samuel, T.; Welsh, K.; Lober, T.; Togo, S. H.; Zapata, J. M.; Reed, J. C. Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and

second mitochondrial activator of caspases. *J. Biol. Chem.* **2006**, *281*, 1080–1090.

(27) Yang, Q. H.; Du, C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. *J. Biol. Chem.* **2004**, *279*, 16963–16970.

(28) For recent reviews, see the following: Wang, S. Design of small-molecule Smac mimetics as IAP antagonists. *Curr. Top. Microbiol. Immunol.* **2010**, *348*, 89–113. Mannhold, R.; Fulda, S.; Carosati, E. IAP antagonists: promising candidates for cancer therapy. *Drug Discovery Today* **2010**, *15*, 210–219. Sun, H.; Nikolovska-Coleska, Z.; Yang, C.-Y.; Qian, D.; Lu, J.; Qiu, S.; Bai, L.; Peng, Y.; Cai, Q.; Wang, S. Design of small-molecule peptidic and nonpeptidic Smac mimetics. *Acc. Chem. Res.* **2008**, *41*, 1264–1277.

(29) <http://clinicaltrials.gov/>.

(30) Sun, H.; Nikolovska-Coleska, Z.; Yang, C.-Y.; Xu, L.; Liu, M.; Tomita, Y.; Pan, H.; Yoshioka, Y.; Krajewski, K.; Roller, P. P.; Wang, S. Structure-based design of potent, conformationally constrained Smac mimetics. *J. Am. Chem. Soc.* **2004**, *126*, 16686–16697.

(31) Sun, H.; Nikolovska-Coleska, Z.; Yang, C.-Y.; Xu, L.; Tomita, Y.; Krajewski, K.; Roller, P. P.; Wang, S. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. *J. Med. Chem.* **2004**, *47*, 4147–4150.

(32) Sun, H.; Nikolovska-Coleska, Z.; Lu, J.; Qiu, S.; Yang, C.-Y.; Gao, W.; Meagher, J.; Stuckey, J.; Wang, S. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. *J. Med. Chem.* **2006**, *49*, 7916–7920.

(33) Sun, H.; Nikolovska-Coleska, Z.; Lu, J.; Meagher, J. L.; Yang, C.-Y.; Qiu, S.; Tomita, Y.; Ueda, Y.; Jiang, S.; Krajewski, K.; Roller, P. P.; Stuckey, J. A.; Wang, S. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. *J. Am. Chem. Soc.* **2007**, *129*, 15279–15294.

(34) Sun, H.; Stuckey, J. A.; Nikolovska-Coleska, Z.; Qin, D.; Meagher, J. L.; Qiu, S.; Lu, J.; Yang, C.-Y.; Saito, N. G.; Wang, S. Structure-based design, synthesis, evaluation and crystallographic studies of conformationally constrained smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). *J. Med. Chem.* **2008**, *51*, 7169–7180.

(35) Peng, Y.; Sun, H.; Nikolovska-Coleska, Z.; Qiu, S.; Yang, C.-Y.; Lu, J.; Cai, Q.; Yi, H.; Wang, S. Design, synthesis and evaluation of potent and orally bioavailable diazabicyclic Smac mimetics. *J. Med. Chem.* **2008**, *51*, 8158–8162.

(36) Zhang, B.; Nikolovska-Coleska, Z.; Zhang, Y.; Bai, L.; Qiu, S.; Yang, C.-Y.; Sun, H.; Wang, S.; Wu, Y. Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases. *J. Med. Chem.* **2008**, *51*, 7352–7355.

(37) Sun, W.; Nikolovska-Coleska, Z.; Qin, D.; Sun, H.; Yang, C.-Y.; Bai, L.; Qiu, S.; Ma, D.; Wang, S. Design, synthesis and evaluation of potent, non-peptidic Smac mimetics. *J. Med. Chem.* **2009**, *52*, 593–596.

(38) Sun, H.; Lu, J.; Liu, L.; Yi, H.; Qiu, S.; Yang, C.-Y.; Deschamps, J. R.; Wang, S. Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. *J. Med. Chem.* **2010**, *53*, 6361–6367.

(39) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. *Angew. Chem., Int. Ed.* **2002**, *41*, 2596–2599.

(40) Vince, J. E.; Wong, W. W.; Khan, N.; Feltham, R.; Chau, D.; Ahmed, A. U.; Benetatos, C. A.; Chunduru, S. K.; Condon, S. M.; McKinlay, M.; Brink, R.; Leverkus, M.; Tergaonkar, V.; Schneider, P.; Callus, B. A.; Koentgen, F.; Vaux, D. L.; Silke, J. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. *Cell* **2007**, *131*, 682–693.

(41) Varfolomeev, E.; Blankenship, J. W.; Wayson, S. M.; Fedorova, A. V.; Kayagaki, N.; Garg, P.; Zobel, K.; Dynek, J. N.; Elliott, L. O.;

Wallweber, H. J.; Flygare, J. A.; Fairbrother, W. J.; Deshayes, K.; Dixit, V. M.; Vucic, D. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. *Cell* **2007**, *131*, 669–681.

(42) Wang, L.; Du, F.; Wang, X. TNF-alpha induces two distinct caspase-8 activation pathways. *Cell* **2008**, *133*, 693–703.

(43) Bertrand, M. J.; Milutinovic, S.; Dickson, K. M.; Ho, W. C.; Boudreault, A.; Durkin, J.; Gillard, J. W.; Jaquith, J. B.; Morris, S. J.; Barker, P. A. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. *Mol. Cell* **2008**, *30*, 689–700.

(44) Lu, J.; Bai, L.; Sun, H.; Nikolovska-Coleska, Z.; McEachern, D.; Qiu, S.; Miller, R. S.; Yi, H.; Shangary, S.; Sun, Y.; Meagher, J. L.; Stuckey, J. A.; Wang, S. SM-164: a novel, bivalent Smac mimetic induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP1/2 and XIAP. *Cancer Res.* **2008**, *68*, 9384–9393.

(45) Yang, C.-Y.; Sun, H.; Chen, J.; Nikolovska-Coleska, Z.; Wang, S. Importance of ligand reorganization free energy in protein–ligand binding-affinity prediction. *J. Am. Chem. Soc.* **2009**, *131*, 13709–13721.

(46) Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Talyor, R. Development and validation of a genetic algorithm for flexible docking. *J. Mol. Biol.* **1997**, *267*, 727–748.

(47) Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein–ligand docking using GOLD. *Proteins* **2003**, *52*, 609–623.

(48) Nikolovska-Coleska, Z.; Wang, R.; Fang, X.; Pan, H.; Tomita, Y.; Li, P.; Roller, P. P.; Krajewski, K.; Saito, N. G.; Stuckey, J. A.; Wang, S. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. *Anal. Biochem.* **2004**, *332*, 261–273.